Denileukin diftitox is a recombinant fusion protein expressing the first 387 amino acid residues of the
diphtheria toxin fragments A and B, followed by the first 122 amino
acid residues of IL-2. The protein binds to IL-2 receptors on T-cells. The diphtheria toxin is then internalized, killing the T-cell.
Denileukin diftitox is indicated for recurrent cutaneous T cell lymphoma whose malignant cells express CD-25, the IL-2 receptor
recombinant fusion protein expressing amino acid residues of diphtheria toxin fragments A & B, followed by the sequence for IL-2
| Source | Link | Revision Date | Access Date |
| ONTAK Prescribing Information | http://www.eisai.com/section.asp?ID=257 | 2007-April | 2008-June-03 |
NO RELIANCE FOR MEDICAL DECISIONSInformation, services and/or other features contained in this web site (including any electronic bulletin board contained therein) are being provided for general educational and informational purposes only and are not intended to be a substitute for independent medical judgment or constitute case-specific medical advice or treatment in any way. Such information, services and/or features are not intended to serve as the primary basis for making personal or professional medical decisions, nor are they intended to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to making any treatment or diagnosis decisions and with any questions you may have regarding a medical condition or its diagnosis or treatment. You should confirm any information obtained from this site with other sources before undertaking any treatment or otherwise taking any actions relating thereto. Any reliance on any information, services or other features contained in this site is solely at your own risk. |
|
Clinical Immunology Society 555 East Wells Street, Suite 1100 Milwaukee, WI 53202-3823 USA Phone: 414/224-8095 | Fax: 414/272-6070 Email: info@clinimmsoc.org © 2001-2011 Clinical Immunology Society | Web Site Disclaimer |
